- $232.53bn
- $259.12bn
- $45.81bn
- 89
- 22
- 73
- 64
REG - AstraZeneca PLC - Update on CALLA Phase III trial for Imfinzi
AnnouncementREG - AstraZeneca PLC - Notice of AGM
AnnouncementREG - AstraZeneca PLC - Settlement of patent litigation for Ultomiris
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - Lynparza approved in US for early breast cancer
AnnouncementREG - AstraZeneca PLC - Update on US review of Fasenra in nasal polyps
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AstraZeneca and Neurimmune close deal for NI006
AnnouncementREG - AstraZeneca PLC - Filing of Form 20-F with SEC
AnnouncementREG - AstraZeneca PLC - Chair succession planning update and Annual Report
AnnouncementREG - AstraZeneca PLC - Enhertu improves PFS and OS in HER2-low BC
AnnouncementREG - AstraZeneca PLC - Saphnelo approved in EU for SLE
AnnouncementREG - AstraZeneca PLC - Lynparza combo delays progression risk in prostate
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - AstraZeneca PLC - AZN: Full year and Q4 2021 results
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
Announcement